Scailyte announces its new advisory board

ScailyteTM is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to discover novel and ultra-sensitive biomarkers from single-cell data. Over the past 3 years, we have established ScaiVisionTM, a proprietary data analytics platform for clinical research, which enables us to achieve groundbreaking discoveries in multiple disease areas. We have validated our approach by discovering our first single-cell biomarker for the detection of skin T-cell lymphoma, which we are currently translating into an in vitro diagnostics application that will radically improve the diagnosis and survival chances for thousands of patients suffering from this disease. We are scaling up our efforts by applying our biomarker discovery approach for multiple indications in oncology and women’s health. In order to strengthen Scailyte’s discovery potential and provide strategic guidance, we have appointed a scientific advisory board consisting of world leading clinicians and scientists. The scientific advisory board is being led by Scailyte’s co-founder, Professor Dr. Manfred Claasen.